190 related articles for article (PubMed ID: 32609933)
1. Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain.
María Molero J; Miñana B; Palacios-Moreno JM; Téllez Martínez-Fornes M; Lorite Mingot D; Agra Rolán A; Carreño Á; Cuervo Pinto R
Int J Clin Pract; 2020 Nov; 74(11):e13602. PubMed ID: 32609933
[TBL] [Abstract][Full Text] [Related]
2. Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain.
Miñana B; Molero JM; Agra Rolán A; Martínez-Fornes MT; Cuervo Pinto R; Lorite Mingot D; Carreño Á; Palacios-Moreno JM
Int J Clin Pract; 2021 Aug; 75(8):e14250. PubMed ID: 33884719
[TBL] [Abstract][Full Text] [Related]
3. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Viktrup L; Hayes RP; Wang P; Shen W
BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
[TBL] [Abstract][Full Text] [Related]
4. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.
Park JS; Koo KC; Kim HK; Chung BH; Lee KS
Medicine (Baltimore); 2019 Oct; 98(42):e17635. PubMed ID: 31626149
[TBL] [Abstract][Full Text] [Related]
5. Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia.
Welliver C; Feinstein L; Ward JB; Kirkali Z; Martinez-Miller EE; Matlaga BR; McVary K
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):269-273. PubMed ID: 34545201
[TBL] [Abstract][Full Text] [Related]
6. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
8. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
[TBL] [Abstract][Full Text] [Related]
9. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management.
Lerner LB; McVary KT; Barry MJ; Bixler BR; Dahm P; Das AK; Gandhi MC; Kaplan SA; Kohler TS; Martin L; Parsons JK; Roehrborn CG; Stoffel JT; Welliver C; Wilt TJ
J Urol; 2021 Oct; 206(4):806-817. PubMed ID: 34384237
[TBL] [Abstract][Full Text] [Related]
10. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
11. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
12. Enhanced clinical decisions for management of benign prostatic hyperplasia using patient-reported outcomes: protocol for a prospective observational study.
Glaser AP; Smith AR; Maglaque D; Helfand BT; Mohamed R; An H; Marquez M; Talaty P; Carolan P; Geller AM; Farina FR; Jensen SE; Griffith JW
BMC Urol; 2024 May; 24(1):110. PubMed ID: 38773430
[TBL] [Abstract][Full Text] [Related]
13. Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom-related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Breyer BN; Huang WY; Rabkin CS; Alderete JF; Pakpahan R; Beason TS; Kenfield SA; Mabie J; Ragard L; Wolin KY; Grubb RL; Andriole GL; Sutcliffe S
BJU Int; 2016 Jan; 117(1):145-54. PubMed ID: 25601300
[TBL] [Abstract][Full Text] [Related]
14. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review.
Haghpanah A; Masjedi F; Salehipour M; Hosseinpour A; Roozbeh J; Dehghani A
Prostate Cancer Prostatic Dis; 2022 Mar; 25(1):27-38. PubMed ID: 34007019
[TBL] [Abstract][Full Text] [Related]
15. Severity profiles in patients diagnosed of benign prostatic hyperplasia in Spain.
Miñana B; Rodríguez-Antolín A; Prieto M; Pedrosa E
Actas Urol Esp; 2013 Oct; 37(9):544-8. PubMed ID: 23856059
[TBL] [Abstract][Full Text] [Related]
16. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.
Gratzke C; Bachmann A; Descazeaud A; Drake MJ; Madersbacher S; Mamoulakis C; Oelke M; Tikkinen KAO; Gravas S
Eur Urol; 2015 Jun; 67(6):1099-1109. PubMed ID: 25613154
[TBL] [Abstract][Full Text] [Related]
17. Potential role of glutathione S-transferase P1 gene polymorphism and metabolic syndrome in lower urinary tract symptoms attributed to benign prostatic hyperplasia.
Zhang W; Li Z; Liu M; Mu Y; He J; Chen P; Liu D; Chen K; Che B; Xu S; Zhang H; Tang K
World J Urol; 2021 Dec; 39(12):4413-4419. PubMed ID: 34228163
[TBL] [Abstract][Full Text] [Related]
18. Natural history of lower urinary tract symptoms in Japanese men from a 15-year longitudinal community-based study.
Fukuta F; Masumori N; Mori M; Tsukamoto T
BJU Int; 2012 Oct; 110(7):1023-9. PubMed ID: 22233355
[TBL] [Abstract][Full Text] [Related]
19. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia.
Wang LW; Li JL; Yu Y; Xiao RH; Huang HW; Kuang RR; Hai B
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):531-535. PubMed ID: 28786061
[TBL] [Abstract][Full Text] [Related]
20. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
